Accordingly, inhibition of TIGIT (genetic- or antibody-based) results in T cell-dependent antitumor responses in several syngeneic models of MM and is currently being evaluated in clinical studies (e.g., NCT04045028 and NCT04150965) (128). Here, TIGIT is linked to Miyoshi myopathy.